Research analyst, medium-term horizon, biotech, small-cap

Time To Back Up The Truck On Cytomedix?

On March 31, 2014, Cytomedix, Inc. (CMXI) reported financial results for the fourth quarter and full year ended December 31, 2013. Total revenues in the quarter were $3.5 million, an increase of 65% over the fourth quarter 2012. Revenues were driven by $3.0 million in product sales, $0.3 million in royalties, and $0.2 million in licensing fees and other income. Product sales consisted of $2.8 million in recorded pass-through sales of Angel to Arthrex, Inc. and $0.2 million in sales of AutoloGel.

Angel sales increased 48% from the fourth quarter 2012. We remind investors that Cytomedix controls the manufacturing of the Angel device and thus records the associated revenue and expenses from the product on its income statement. Sales of

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details